Prostate cancer (PCa) is the second most common malignancy among men in the world.
Castration-resistant prostate cancer (CRPC) is the lethal form of the disease, which …

Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

Prostate cancer (PCa) is the most common cancer in men. The androgen receptor (AR) has
a pivotal role in the pathogenesis and progression of PCa. Many therapies targeting AR …

Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

A large number of novel therapeutics is currently undergoing clinical evaluation for the
treatment of prostate cancer, and small molecule signal transduction inhibitors are a …

The PI3K signaling pathway is activated in a majority of cancer types. It promotes
tumorigenesis by regulating nutrient metabolism, cell proliferation, survival, migration, and …

Background: Androgen receptor (AR) and the phosphatidylinositol-3 kinase (PI3K) signaling
are two of the most important pathways implicated in prostate cancer. Previous work has …

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of
the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the …

Abstract The PI3K/Akt pathway is an actively pursued therapeutic target in oncology. In
prostate cancer, the activation of this pathway appears to be characteristic of many …